Am-12

Strychnos Ignatii Whole, Ferrosoferric Phosphate, And Sepia Officinalis Juice


Dna Labs, Inc.
Human Otc Drug
NDC 58264-0351
Am-12 also known as Strychnos Ignatii Whole, Ferrosoferric Phosphate, And Sepia Officinalis Juice is a human otc drug labeled by 'Dna Labs, Inc.'. National Drug Code (NDC) number for Am-12 is 58264-0351. This drug is available in dosage form of Solution. The names of the active, medicinal ingredients in Am-12 drug includes Ferrosoferric Phosphate - 8 [hp_X]/mL Sepia Officinalis Juice - 12 [hp_X]/mL Strychnos Ignatii Whole - 8 [hp_X]/mL . The currest status of Am-12 drug is Active.

Drug Information:

Drug NDC: 58264-0351
The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Proprietary Name: Am-12
Also known as the trade name. It is the name of the product chosen by the labeler.
Product Type: Human Otc Drug
Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing.
Non Proprietary Name: Strychnos Ignatii Whole, Ferrosoferric Phosphate, And Sepia Officinalis Juice
Also known as the generic name, this is usually the active ingredient(s) of the product.
Labeler Name: Dna Labs, Inc.
Name of Company corresponding to the labeler code segment of the ProductNDC.
Dosage Form: Solution
The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Status: Active
FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved.
Substance Name:FERROSOFERRIC PHOSPHATE - 8 [hp_X]/mL
SEPIA OFFICINALIS JUICE - 12 [hp_X]/mL
STRYCHNOS IGNATII WHOLE - 8 [hp_X]/mL
This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.
Route Details:SUBLINGUAL
The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.

Marketing Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Marketing Category: UNAPPROVED HOMEOPATHIC
Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Marketing Start Date: 01 Jan, 1990
This is the date that the labeler indicates was the start of its marketing of the drug product.
Marketing End Date: 16 Jun, 2026
This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Listing Expiration Date: 31 Dec, 2023
This is the date when the listing record will expire if not updated or certified by the firm.

OpenFDA Information:

An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
Manufacturer Name:DNA Labs, Inc.
Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC.
Original Packager:Yes
Whether or not the drug has been repackaged for distribution.
UNII:91GQH8I5F7
QDL83WN8C2
6YSJ329777
Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information.

Packaging Information:

Package NDCDescriptionMarketing Start DateMarketing End DateSample Available
58264-0351-129.57 mL in 1 BOTTLE, GLASS (58264-0351-1)01 Jan, 1990N/ANo
Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together.

Purpose:

Regulates energy flow in the bladder meridian.

Product Elements:

Am-12 strychnos ignatii whole, ferrosoferric phosphate, and sepia officinalis juice alcohol water strychnos ignatii whole strychnos ignatii whole ferrosoferric phosphate ferrosoferric phosphate sepia officinalis juice sepia officinalis juice

Indications and Usage:

Indications regulates energy flow in the bladder meridian.

Warnings:

Warnings use only if cap seal is unbroken. as with drugs if you are pregnant or nursing a baby seek professional advice before using this product. keep this and all medication out of the reach of children.

Dosage and Administration:

Suggested dosage 5 to 10 drops twice a day, meridian energy excess 1 to 5 drops t.i.d, meridian lacking in energy 10 to 20 drops t.i.d.

Package Label Principal Display Panel:

Principal display panel - 1 fl. oz. bottle label dynamic nutritional associates, inc. am-12 bladder acupuncture meridian 1 fl. oz. principal display panel - 1 fl. oz. bottle label


Comments/ Reviews:

* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.